Form 13-F position report

CUE BIOPHARMA INC

Reported by BlackRock Inc

CUE CUSIP 22978P106 Manager CIK 0002012383

Reported 0 shares, down 449,161 (100.0%) from the prior quarter.

Reported value -100.0%; share count -100.0% vs. the prior quarter.

Reduced
% of reported 13F value 0 This manager · Q2 2026
Shares 0 Quarter-end amount reported
Reported value $0 Fair value at quarter end
Consecutive quarters held 34 Through Q2 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 25903000
2022-03-31 11622000
2022-06-30 2072000
2022-09-30 1737000
2022-12-31 2001217
2023-03-31 2372000
2023-06-30 7541171
2023-09-30 4896585
2023-12-31 6174340
2024-03-31 4241354
2024-06-30 938353
2024-09-30 432342
2024-12-31 696458
2025-03-31 578671
2025-06-30 306463
2025-09-30 322813
2025-12-31 137174
2026-03-31 103261
2026-06-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

19 quarters
Quarterly reported position history for CUE BIOPHARMA INC held by BlackRock Inc.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q2 2026 Reduced 0 -449,161 (-100.0%) 0 $0 2026-08-07
Q1 2026 Reduced 449,161 -1 (0.0%) < 0.01% $103,261 2026-05-13
Q4 2025 Unchanged 449,162 0 (0.0%) < 0.01% $137,174 2026-02-12
Q3 2025 Unchanged 449,162 0 (0.0%) < 0.01% $322,813 2025-11-12
Q2 2025 Reduced 449,162 -186,041 (-29.3%) < 0.01% $306,463 2025-08-12
Q1 2025 Reduced 635,203 -3,749 (-0.6%) < 0.01% $578,671 2025-05-02
Q4 2024 Added 638,952 +67,977 (11.9%) < 0.01% $696,458 2025-02-07
Q3 2024 New 570,975 +570,975 (0.0%) < 0.01% $432,342 2024-11-13
Q2 2024 Reduced 756,736 -1,487,367 (-66.3%) < 0.01% $938,353 2024-08-13
Q1 2024 Reduced 2,244,103 -94,662 (-4.0%) < 0.01% $4,241,354 2024-05-10
Q4 2023 Added 2,338,765 +209,815 (9.9%) < 0.01% $6,174,340 2024-02-13
Q3 2023 Added 2,128,950 +62,876 (3.0%) < 0.01% $4,896,585 2023-11-13
Q2 2023 Added 2,066,074 +1,401,648 (211.0%) < 0.01% $7,541,171 2023-08-11
Q1 2023 Reduced 664,426 -37,755 (-5.4%) < 0.01% $2,372,000 2023-05-12
Q4 2022 Reduced 702,181 -76,527 (-9.8%) < 0.01% $2,001,217 2023-02-13
Q3 2022 Reduced 778,708 -53,217 (-6.4%) < 0.01% $1,737,000 2022-11-14
Q2 2022 Reduced 831,925 -1,549,342 (-65.1%) < 0.01% $2,072,000 2022-08-12
Q1 2022 Added 2,381,267 +90,998 (4.0%) < 0.01% $11,622,000 2022-05-12
Q4 2021 Added 2,290,269 +129,811 (6.0%) < 0.01% $25,903,000 2022-02-10
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

54 managers reported CUE BIOPHARMA INC for Q2 2026.

Managers reporting CUE BIOPHARMA INC in Q2 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
IFP Advisors Inc Added 100 +96 < 0.01% $55 11 qtrs
PREVAIL INNOVATIVE WEALTH ADVISORS LLC Reduced 0 -18,987 0 $0 5 qtrs
Sigma Planning Corp Reduced 0 -38,750 0 $0 30 qtrs
Barclays PLC Reduced 0 -6,029 0 $0 34 qtrs
MIRAMONTES CAPITAL LLC Reduced 0 -26,041 0 $0 3 qtrs
Vanguard Global Advisers LLC Reduced 0 -12,997 0 $0 2 qtrs
UBS Group AG Reduced 0 -88,350 0 $0 34 qtrs
STIFEL FINANCIAL CORP Reduced 0 -246,556 0 $0 29 qtrs
Beacon Pointe Advisors LLC Reduced 0 -10,000 0 $0 2 qtrs
ADVISORY RESEARCH INC Reduced 0 -257,225 0 $0 22 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2026
Filed
August 07, 2026
Filing type
13F-HR
Position type
COM

Voting authority reported

No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.